Phase
Startup
Asgard Therapeutics
Asgard Therapeutics is a spin-off from Lund University aiming to advance cancer immunotherapies by developing a paradigm-shifting gene therapy – TrojanDC. Asgard is developing the world’s first cancer immunotherapy based on direct cell reprogramming, forcing cancer cells to become immunogenic and unleashing the immune system against cancer.
Cristiana Pires holds a degree in Pharmaceutical Sciences and PhD in Cell Reprogramming. She founded Asgard Therapeutics in 2018 together with the other two inventors of TrojanDC, Associate Professor Filipe Pereira and Fábio Rosa, MSc. Now, by combining her pharmaceutical and scientific background with entrepreneurship experience, Cristiana is motivated to bring TrojanDC to the patients.
Did you know?
Asgard’s scientific founders are from Portugal and decided to honor the Swedish affiliation by choosing a name inspired by the Norse Mythology.
Medicines for acute systemic inflammatory diseases
Cancer immunotherapies based in cell reprogramming
A "check-in buddy" for the elderly
Cell factories for dairy processing
Implants of magnesium alloys
Digital service for patients
Digital communication tool for titrating medicine
Medical device that reduces pain during vein operation
Cloud-based solutions for genomics data
A reusable, user-friendly, and sustainable pregnancy test
Digital assistive device for post-surgical rehabilitation
Develops the first effective treatment for hypothyroidism
Builds gene therapy viral vectors
Bio-based vegan coating for fruits and vegetables
Equipment that improves the function of cultivated cells
Medtech solution for preventing pressure ulcers
A new suturing choice for abdominal wall closure
Converting waste flows into valuable raw materials
Gene editing analysis solution
Novel radioimmunotherapy curing cancer
Safer medical needles for prostate biopsy
eHealth clinic for obesity treatment
